News | October 01, 2010

Early-Warning Coronary Occlusion System Receives CE Mark


October 1, 2010 – An early-warning system for detecting coronary occlusion has received the CE mark for commercial sale in Europe. The AngelMed Guardian System, by Angel Medical Systems, is designed to detect coronary occlusion from thrombotic events, such as plaque ruptures, and alert the patient, often before any symptoms occur.

The implantable device is about the size of a pacemaker and has vibrational warning. It connects to the heart using a standard pacemaker lead. External alerts are also provided by a pager-like system.

The AngelMed Guardian is currently being tested in the United States in the ALERTS Phase II Clinical Study.

"Over the past two decades, it has routinely taken patients two to three hours to arrive at the hospital with a heart attack. Our initial studies indicate that this device may reduce that time to approximately 20 minutes,” said C. Michael Gibson, M.D., Harvard Medical School and principal leader of the study. “When time is muscle, every minute counts and our hope is that survival will be improved."

For more information: www.angel-med.com


Related Content

Feature | ECG | Samir Awasthi, MD, PhD

For decades, medicine has treated the electrocardiogram as a familiar, inexpensive and indispensable test, but also as ...

Home June 16, 2026
Home
News | ECG

June 2, 2026 —HeartSciences Inc. has announced the commercial release of MyoVista Insights version 1.3, a major platform ...

Home June 05, 2026
Home
News | ECG

June 2, 2026 — AccurKardia, Inc. has been granted US Patent No. 12,620,488 for the company's proprietary machine ...

Home June 02, 2026
Home
News | ECG

May 7, 2026 — AccurKardia, a provider of ECG-based diagnostics technology, recently announced that AK+ Guard has been ...

Home May 08, 2026
Home
News | ECG

April 15, 2026 – AliveCor has received CE Mark (Conformité Européenne) for the Kardia 12L electrocardiogram (ECG) System ...

Home April 15, 2026
Home
News | ECG

March 4, 2026 — HeartBeam, Inc. has announced a commercial partnership with ClearCardio. In addition to serving as ...

Home March 06, 2026
Home
News | ECG

March 3, 2026 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for treating cardiovascular and ...

Home March 04, 2026
Home
News | ECG

Feb. 10, 2026 – AccurKardia, a provider of ECG-based diagnostics technology, recently announced results from a new study ...

Home February 24, 2026
Home
News | ECG

Feb. 18, 2026 — Researchers at the Mount Sinai Kravis Children’s Heart Center led a multicenter effort to develop and ...

Home February 20, 2026
Home
News | ECG

Dec. 10, 2025 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to HeartBeam, Inc. for its 12 ...

Home February 16, 2026
Home
Subscribe Now